TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03047876

Intervention type: PROCEDURE
Intervention: aortic arch surgery
Description: Children, from neonatal age to late infancy, undergoing aortic arch surgery (n=20) will have cerebral perfusion measurements during surgery, including during the cooling and rewarming phase, whilst on cardiopulmonary bypass and during the recovery period in the intensive care unit
Study: NCT02202837

Intervention type: DRUG
Intervention: etanercept
Description: etanercept 1 x 50 mg/week or 2 x 25mg/week

Intervention type: DRUG
Intervention: etanercept
Description: etanercept 1 x 50 mg/week or 2 x 25mg/week
Study: NCT02585154

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)
Description: 'Classical' high-frequency Deep Brain Stimulation, which is applied irrespective of ongoing brain activity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: closed-loop Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)
Description: Deep Brain Stimulation, which is applied depending on ongoing brain activity.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Deep Brain Stimulation off
Description: Deep Brain Stimulation is turned off.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: local field potentials and electroencephalography recordings
Description: Simultaneous recordings of local field potentials from subthalamic nucleus and electroencephalography
Study: NCT04039685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effects of an eight weeks combined (aerobic+resistance) exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue
Description: The investigators evaluated the effects of an eight weeks combined (aerobic+resistance) exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
Study: NCT02756715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol group
Description: Patient will be anesthetized by using propofol infusion during operation.
Study: NCT02585154

Intervention type: DEVICE
Group type: OTHER
Intervention: local field potentials and electroencephalography recordings
Description: Simultaneous recordings of local field potentials from subthalamic nucleus and electroencephalography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: local field potentials and electroencephalography recordings
Description: Simultaneous recordings of local field potentials from subthalamic nucleus and electroencephalography
Study: NCT04418674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: in this group, patient will receive ketamine at 0.3mg/kg intravenously.
Study: NCT02339090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somavaratan
Description: Somavaratan will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhGH
Description: rhGH will be administered per dose and schedule specified in the arm description.
Study: NCT01168687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam (Keppra)
Description: Group A: Twenty moderate to heavy social alcohol users will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.~Group B: Twenty moderate to heavy social alcohol users will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days.
Study: NCT04418674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: In this group, the patients will receive fentanyl at 1.5mcg/kg intavenously.
Study: NCT02495831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Description: Diclofenac sodium 50 mg single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac sodium and safinamide
Description: Diclofenac 50 mg single dose and safinamide 200 mg single dose
Study: NCT00112008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: De Novo Administration of Darbepoetin Alfa
Description: Administration Q2W for 18 weeks. starting dose is 0.75 mcg/kg rounded to the nearest dose: 20, 30, 40, 50, 60, 80, 100, 150, 200 0r 300 mcg. Titrate to maintain Hb within 11.0 - 13.0 g/dL
Study: NCT02829255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: altitude exposure
Description: altitude exposure
Study: NCT01228864

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality of life
Description: survey

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life
Study: NCT01605968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCT Silver Bandage
Description: Activated carbon fiber impregnated with silver particles

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel® Ag. Dressing
Description: Antimicrobial primary dressing incorporating the unique gelling action of Hydrofiber® Technology with ionic silver for wounds that are infected or at risk of infection.
Study: NCT02756715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane group
Description: Patient will be anesthetized by using desflurane inhalation during operation.
Study: NCT01066078

Intervention type: OTHER
Intervention: Echocardiography and SonR recording
Study: NCT02735265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: 12 training sessions (90 minutes a time, 2 times a week) IG:45 minute of Kinect for Xbox games and 45 minute of standard treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: CG: 90 minute of standard treatment. 12 training sessions (90 minutes a time, 2 times a week)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: CG: 90 minute of standard treatment. 12 training sessions (90 minutes a time, 2 times a week)
Study: NCT01068249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg daily by mouth every day, at same time as Everolimus.
Study: NCT00875784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TREXIMA™
Description: sumatriptan succinate / naproxen sodium tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TREXIMA™
Description: sumatriptan succinate / naproxen sodium tablet
Study: NCT01068249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 (Everolimus)
Description: 10 mg by mouth daily
Study: NCT03256682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress management counseling
Description: stress management counseling based on CBT and relaxation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress management counseling
Description: stress management counseling based on CBT and relaxation
Study: NCT00875784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMITREX® (4mg)
Description: sumatriptan succinate injection (4mg) administered using the IMITREX STATdose System®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMITREX® (6mg)
Description: sumatriptan succinate injection (6mg) administered using the IMITREX STATdose System®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMITREX Tablet 100mg
Description: IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet
Study: NCT04026438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Phosphate Injection
Description: One ml of the preparation contains 3 mmol of phosphorous which when equated with RDA 10ml ie 30 mmol of preparation will be supplemented. The preparation is given slowly, intravenously over 4 hours diluted in 500 ml normal saline
Study: NCT01123278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Testosterone transdermal gel 50 mg/day (5 gr)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo transdermal gel (5 gr)
Study: NCT01623817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin HCL
Description: Loading dose of 30mg/kg via central or peripheral intravenous infusion during 2 or 3 hours.~Maintenance dose of vancomycin is 15mg/kg twice a day or 1g twice a day.
Study: NCT05427071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic seed localization
Description: Magnetic seed guided localization
Study: NCT01052987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranilast
Description: Tranilast tablets, 300 mg, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol tablets 300 mg, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination - Tranilast and Allopurinol
Description: Tranilast, 300 mg QD; Allopurinol 300 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400 mg Allopurinol
Description: 400 mg Allopurinol administered once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose combination
Description: Combination of Tranilast 300 mg once daily for 7 days plus Allopurinol 400 mg once daily for 7 days
Study: NCT00931671

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise training
Description: aerobic exercise training
Study: NCT01168687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam (Keppra)
Description: Group A: Twenty moderate to heavy social alcohol users will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.~Group B: Twenty moderate to heavy social alcohol users will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04088747

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Imaging
Description: B-mode ultrasound pictures of the upper Trapezius were collected from both left and right sides.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Imaging
Description: B-mode ultrasound pictures of the upper Trapezius were collected from both left and right sides.
Study: NCT04138784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized comprehensive rehabilitation program
Description: The program general contents were pain education, joint protection techniques, general care lifestyle habits, which were complemented by a problem-based session. The program plan was designed to fit patients' goals, priorities, and lifestyles after an initial interview.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic training
Description: Patients received a 45 min-water exercise program which included balance and proprioception activities, isometric exercise, flexibility exercises, core stabilization exercises and aerobic/endurance exercises. All sessions were developed in groups and addressed by a qualified professional.
Study: NCT03978416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Weight for Living for Hispanics
Description: The Healthy Weight for Living (HWL) intervention, previously developed at the Energy Metabolism Laboratory (HNRCA), is broadly informed by the same behavior change theories as other interventions. For example, it also recognizes individual and environmental factors as potential areas to support behavior change for weight regulation, and provides practical tools for facilitating new habits. However, the HWL places greater emphasis on the role of biology in influencing eating behavior, giving a central role to hunger and food cravings as modulators of eating behavior. Therefore, HWL does not emphasize self-monitoring food intake and does not require increasing physical activity for effectiveness. The new intervention also targets autonomous motivation and prioritizes ease of implementation.~Information from focus groups and sequential pilots will be used to develop a culturally tailored prototype version of Healthy Weight for Living that is acceptable for Hispanic older adults.
Study: NCT00855764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Solution, IV, 100 mg/m2, weekly for 6 of 7 weeks, until evidence of disease progression or unacceptable side effects became apparent
Study: NCT03939949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Mindfulness
Description: Those in the high mindfulness group will also receive questions about their current pain intensity and unpleasantness in both the morning and evening for six days. In order to emphasize the variability in pain, participants will receive these text messages on a variable schedule. In addition, they will sent instructions every morning to pay attention to variability in their pain throughout the day and asked to report on how their pain is changing over time as a part of each text message prompt.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Mindfulness
Description: Those in the low mindfulness group, who will receive receive two text messages per day (one at at 9am and one at 9pm) for six days, each prompting them to write about the activity they are currently engaged in. They will also be prompted with the 9pm text to report on their pain intensity and unpleasantness at that time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants in the active control group will receive 2 text messages per day for six days (one at 9am and one at 9pm) asking them to report on the activity they are currently engaged in.
Study: NCT00872326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Mononuclear Cells
Description: Infusion \> 80 millions mononuclear cells. Intraarterial administration at popliteal artery level. Infusion during 3 minutes with antegrade blockage of arterial flow.
Study: NCT01058928

Intervention type: OTHER
Intervention: Observation of fluid leakage around tracheal tube cuffs
Description: One milliliter of Evans blue diluted in 3.5 mL of saline solution is carefully instilled on the top of the tracheal tube cuff. In the operating room, one hour and five hours after intubation, fiberoptic bronchoscopy was performed to detect the possible presence of blue dye in the trachea. If a blue spot was seen on the trachea caudal to the tube's tip on any occasion, leakage was confirmed and the experiment was finished.

Intervention type: OTHER
Intervention: Observation of fluid leakage around tracheal tube cuffs
Description: One milliliter of Evans blue diluted in 3.5 mL of saline solution is carefully instilled on the top of the tracheal tube cuff. In the operating room, one hour and five hours after intubation, fiberoptic bronchoscopy was performed to detect the possible presence of blue dye in the trachea. If a blue spot was seen on the trachea caudal to the tube's tip on any occasion, leakage was confirmed and the experiment was finished.
Study: NCT03567525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymph node dissection using the peritoneal iliac flap approach to seal lymphatic vessels
Description: After pelvic lymph node dissection, lymphatic vessels will be sealed by formation of a peritoneal iliac flap in which the bladder in folded over the area of lymph node dissection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgical approach
Description: After pelvic lymph node dissection, lymphatic vessels will be sealed using the standard approach
Study: NCT04066920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBER salvage chemotherapy followed by ibrutinib maintenance therapy
Description: Induction therapy with IBER (up to 6 cycles) \[ Ibrutinib 560 mg/d on D1-21 + Rituximab 375 mg/m2 on D1 (on D1/8/15 in C1) + Ifosfamide 3.75 g/m2 on D2 + Etoposide 100 mg/m2 on D2-4 \], followed by ibrutinib 560 mg/d maintenance therapy for up to 6 months
Study: NCT00559364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viokase® 16
Description: Patients assigned to Viokase® 16 will be given 22 tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients assigned to placebo will be given 22 matching placebo tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Proton pump inhibitor (PPI)
Description: Patients on PPI during Screening will continue their usual PPI therapy throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI)
Description: Patients on PPI during Screening will continue their usual PPI therapy throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omeprazole
Description: Patients not using PPI therapy at Screening will be given omeprazole 20 milligram orally once daily throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Patients not using PPI therapy at Screening will be given omeprazole 20 milligram orally once daily throughout the study.
Study: NCT02056067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise intervention group will receive social, behavioral support and research staff contact time to encourage them to increase their activity level to include twice weekly strength-training sessions and 150 min of walking/week (e.g., three 50-min walking sessions or five 30-min walking sessions) over 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control (Health Education)
Description: The Attention Control Group will be provided written information that emphasizes the importance of a healthy lifestyle. Participants will be encouraged to follow the NCI and ACS physical activity guidelines. This procedure was followed in our exercise trials, with no increase in physical activity levels observed at follow-up among women in the usual care group. Attention Control participants will also receive frequent contacts throughout the 12 month intervention. Each month, women randomized to attention control will be contacted by phone to discuss a health education topic of interest
Study: NCT03167502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eccentric work
Description: patient will follow 2 eccentric trainings per week during 6 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: concentric work
Description: patient will follow 2 concentric trainings per week during 6 weeks
Study: NCT00489099

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V232 Modified Process Hepatitis B Vaccine: Lot A

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V232 Modified Process Hepatitis B Vaccine: Lot B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V232 Modified Process Hepatitis B Vaccine: Lot C

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: V232 Current Process Hepatitis B Vaccine
Study: NCT03233451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-behavioral intervention
Description: The psycho-behavioral intervention included 12-week weekly guided psychological intervention (8 modules of behavioral intervention) and 24-week monthly maintenance psychological support.
Study: NCT03809000

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: daily fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: daily fractions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH analog
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH analog
Description: Injection
Study: NCT01993732

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrieval and Cryopreservation
Description: Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed.
Study: NCT03384966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selatogrel
Description: Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) or matching placebo will be reconstituted with 1 mL of water for injection. Further dilution with 1 mL sodium chloride (NaCl) 0.9% will be performed for preparation of the dose of 8 mg selatogrel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for subcutaneous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selatogrel
Description: Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
Study: NCT03129906

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rice protein
Study: NCT01795157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CCADSS
Description: Questionnaire is transferred wireless to the physician's PC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pen-paper
Description: Questionnaire completed and transferred to the physician using standard methods
Study: NCT01427673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bipap procedure
Description: Overlap patients randomized to Bipap titrated per AASM guidleines with an IPAP to EPAP diffrence of at least 8 cm H2O.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipap procedure
Description: Overlap patients randomized to Bipap titrated per AASM guidleines with an IPAP to EPAP diffrence of at least 8 cm H2O.
Study: NCT05410314

Intervention type: DRUG
Intervention: Myo-Inositol and D-Chiro-Inositol (MIC)
Description: Both groups were followed up for 12 months, in T0 (during first evaluation), and T12 (after twelve months) with blood test for AMH (ng/ml).
Study: NCT00137449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: 37.5 mg once daily on a continuous daily dosing schedule. Study medication continued as long as patient was obtaining clinical benefit, or until significant toxicity, or withdrawal of consent, for up to 1 year on study.